XXXX /prostatic acid phosphatase ratio is significant prognostic factor in @entity1 with @entity5 .

@entity1 @entity263 @entity5 @entity880 @entity2786 @entity1486
OBJECTIVES: Novel prognostic indexes clinically applicable for @entity1 with @entity5 are needed because @entity1486 (PSA) tests occasionally fail to reflect the prognostic outcome. We investigated various clinicopathologic parameters in @entity1 with @entity5 and evaluated the utility of the PSA/prostatic acid phosphatase ( @entity2786 ) ratio as a prognostic index. METHODS: We reviewed 241 @entity1 with @entity5 , who were treated in Niigata Cancer Center Hospital from 1992 to 2004. Survival curves were generated using the Kaplan-Meier method. Univariate and multivariate analyses of survival associations, including age, performance status, clinical presentation, disease localization, pathologic findings, and serologic markers, were conducted using the log-rank test and Cox proportional hazard models. RESULTS: The 5-year overall survival rate using the Kaplan-Meier method for all 241 @entity1 was 43.0%. No significant difference was found in the survival rates according to PSA level. However, the 5-year survival rate was significantly lower in @entity1 with a PSA/ @entity2786 ratio of less than 3.0 (P = 0.0022): 24.2% and 48.0% in those with a PSA/ @entity2786 ratio of less than 3.0 and 3.0 or greater, respectively. On multivariate analysis using the proportional hazards model, the statistically significant prognostic factors of overall survival were alkaline phosphatase (P = 0.0413), @entity880 dehydrogenase (P = 0.0409), and the PSA/ @entity2786 ratio (P = 0.0113). CONCLUSIONS: The PSA/ @entity2786 ratio is a valuable prognostic indicator in @entity1 with @entity5 . Although our study found that other laboratory tests also had a prognostic influence, the PSA/ @entity2786 ratio was an essential index implicated in the physiopathology of @entity263 .
